In a phase 1b clinical trial assessing the antitumor activity of an anti-PD-L1 antibody in patients with locally advanced or metastatic breast cancer, the confirmed objective response rate (ORR) for BC was 3.0% and 5.2% for TNBC. Here, CD274 is linked to breast cancer.